Prostatic specific antigen, ultrasensitive

Alphabetical Test listing

Prostatic specific antigen, ultrasensitive-994

  
Prostatic specific antigen, ultrasensitive
  
994
  
LAB994
  
MSO
  
PSA, third generation
PSA, ultrasensitive
  

Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells lining the prostatic ducts and acini. Normally, it is secreted into the prostatic ducts and is present only in prostate tissue, prostatic fluid, and seminal plasma. PSA is produced by normal, hyperplastic, and cancerous prostatic tissue. PSA is used as a tumor marker for the early detection of prostate cancer and in other areas of prostate disease management.

PSA sampling should not be performed for at least six weeks after prostatic biopsy. This test is intended for use as an aid in the management of patients following surgical or medical treatment for prostate cancer. Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.

  

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R).

It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

  
Serum
  
  
1.0 mL
  
0.7 mL
Submitting the minimum volume does not allow for repeat testing
  

Spin

  

Gold serum separator (SST) tube

  
Lithium heparin (Li hep) plasma
  
  

Red: Spin and separate

Lt green: Spin

  

Transfer vial/tube with cap - 12mL (LabCorp)

or

Lt green plasma separator (PST)

  

Ambient (preferred) - 7 days

Refrigerated - 7 days

Frozen - 14 days

  
LabCorp Burlington (140731): R-NX
  
Mo - Fr, Su
  
1 - 3 days
  

Electrochemiluminescence Immunoassay (ECLIA)

  

Male: 0.000-4.000 ng/mL

According to the American Urological Association (AUA), serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value ≥0.20 ng/mL followed by a subsequent confirmatory PSA value ≥0.20 ng/mL.

  
Biotin interference alert - see Patient preparation
  
84153
  
Yes
  
  
Result 35741-8
  
05/24/2019
  
08/13/2021
  
08/24/2021